Literature DB >> 33586064

Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer.

Samilia Obeng-Gyasi1,2,3, Sarah Asad4, James L Fisher4,5, Saurabh Rahurkar6, Daniel G Stover4,7,5,8.   

Abstract

BACKGROUND: A subset of triple-negative breast cancer (TNBC) is characterized by aggressive disease, rapid relapse, and mortality within 24 months of diagnosis, termed "rapid relapse" TNBC (rrTNBC). The objective of this study is to define the association between sociodemographic variables and surgical management among rrTNBC patients in the Surveillance, Epidemiology and End Results (SEER) Program.
METHODS: TNBC patients diagnosed from January 1, 2010 to December 31, 2014 with local or regional disease were identified in SEER. Patients were stratified as rrTNBC, defined as disease specific mortality ≤ 24 months after diagnosis, and non-rrTNBC. Chi-squared tests, t tests, and multivariable logistic regression were used to assess the association of rapid relapse with sociodemographic variables and surgical management.
RESULTS: The cohort included 8% (1378/17,369) rrTNBCs. A higher proportion of rrTNBC patients had no surgery (11.7%) compared with non-rrTNBC (2.6%). Omission of axillary staging among patients who had surgery was 6.2% rrTNBC versus 4.5% non-rrTNBC. Black race (odds ratio [OR] 1.22, 95% confidence interval [CI] 1.05-1.43; p = 0.01; white ref), Medicaid or no insurance (Medicaid OR 1.53, 95% CI 1.31-1.79; p < 0.001; no insurance OR 1.74, 95% CI 1.31-2.32; p < 0.001; private ref), single status (OR 1.19, 95% CI 1.01-1.39; p = 0.03; married ref), no breast (OR 2.35, 95% CI 1.77-3.11; p < 0.001; mastectomy ref), and no axillary surgery (OR 1.44, 95% CI 1.13-1.83; p = 0.003 axillary surgery ref) were associated with rapid relapse.
CONCLUSIONS: Medicaid or no insurance, single status, black race, and no surgery are associated with higher odds of rrTNBC in SEER. These results indicate an interplay between socioeconomic factors, clinical and genomic variables may be disproportionately contributing to worse outcomes among a subset of TNBC patients.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 33586064      PMCID: PMC9143975          DOI: 10.1245/s10434-021-09688-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  44 in total

Review 1.  Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman; Mah-Jabeen Soobader; S V Subramanian; Rosa Carson
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

Review 2.  Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations.

Authors:  C P Hunter
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

3.  Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data.

Authors:  Mandi Yu; Zaria Tatalovich; James T Gibson; Kathleen A Cronin
Journal:  Cancer Causes Control       Date:  2013-11-01       Impact factor: 2.506

4.  Cancer statistics for African Americans, 2019.

Authors:  Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-02-14       Impact factor: 508.702

5.  The Effect of Hospital Volume on Breast Cancer Mortality.

Authors:  Rachel A Greenup; Samilia Obeng-Gyasi; Samantha Thomas; K Houck; Whitney O Lane; Rachel C Blitzblau; Terry Hyslop; E Shelley Hwang
Journal:  Ann Surg       Date:  2018-02       Impact factor: 12.969

6.  The implications of insurance status on presentation, surgical management, and mortality among nonmetastatic breast cancer patients in Indiana.

Authors:  Samilia Obeng-Gyasi; Lava Timsina; Kathy D Miller; Kandice K Ludwig; Carla S Fisher; David A Haggstrom
Journal:  Surgery       Date:  2018-08-28       Impact factor: 3.982

7.  The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis.

Authors:  Paula M Lantz; Mahasin Mujahid; Kendra Schwartz; Nancy K Janz; Angela Fagerlin; Barbara Salem; Lihua Liu; Dennis Deapen; Steven J Katz
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

8.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

9.  Prognostic significance of marital status in breast cancer survival: A population-based study.

Authors:  María Elena Martínez; Jonathan T Unkart; Li Tao; Candyce H Kroenke; Richard Schwab; Ian Komenaka; Scarlett Lin Gomez
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

10.  Why does specialist treatment of breast cancer improve survival? The role of surgical management.

Authors:  D Kingsmore; D Hole; C Gillis
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more
  2 in total

1.  Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database.

Authors:  Enrique O Martinez; Julie M Jorns; Amanda L Kong; Julie Kijak; Wen-Yao Lee; Chiang-Ching Huang; Chandler S Cortina
Journal:  Ann Surg Oncol       Date:  2022-07-04       Impact factor: 4.339

2.  A novel nomogram for predicting long-term heart-disease specific survival among older female primary breast cancer patients that underwent chemotherapy: A real-world data retrospective cohort study.

Authors:  Chao Huang; Zichuan Ding; Hao Li; Zongke Zhou; Min Yu
Journal:  Front Public Health       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.